View article

Background

Most people who are newly diagnosed with non‐small cell lung cancer (NSCLC) have advanced disease. For these people, survival is determined by various patient‐and tumor‐related factors, of which the performance status (PS) is the most important prognostic factor. People with PS 0 or 1 are usually treated with systemic therapies, whereas people with PS 3 or 4 most often receive supportive care. However, treatment for people with PS 2 without a targetable mutation remains unclear. Historically, people with a PS 2 cancer are frequently excluded from (important) clinical trials because of poorer outcomes and increased toxicity. We aim to address this knowledge gap, as this group of people represents a significant proportion (20% to 30%) of the total population with newly diagnosed lung cancer.

Objectives

To identify the best first‐line therapy for advanced lung cancer in people with performance …